Ftse Mib
33.577,42
-0,39%
DAX
18.155,24
-0,04%
S&P 500
5.466,33
-0,05%
NASDAQ
17.760,11
0,24%
Bitcoin
60.993,57
-1,32%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verve Therapeutics Inc (VERV) Verve Therapeutics Inc (VERV) Notizie

Verve Therapeutics Inc

VERV
5,115
-0,115 (-2,20%)
Ultimo aggiornamento: 20:24:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/6/202422:07EDGAR2Form 8-K - Current report
31/5/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
31/5/202413:14EDGAR2Form 8-K - Current report
31/5/202413:00GLOBEVerve Therapeutics Announces Leadership Update
30/5/202422:01GLOBEVerve Therapeutics to Participate in Upcoming Investor..
08/5/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202413:15EDGAR2Form 8-K - Current report
08/5/202413:00GLOBEVerve Therapeutics Announces Pipeline Progress and Reports..
07/5/202413:00GLOBEVerve Therapeutics Announces Dosing of First Patient in..
03/5/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
02/4/202413:00GLOBEVerve Therapeutics Announces Updates on its PCSK9 Program
28/3/202421:51GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
01/3/202422:01GLOBEVerve Therapeutics Announces Inducement Grants under Nasdaq..
27/2/202414:32EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202414:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:45EDGAR2Form 8-K - Current report
27/2/202413:30GLOBEVerve Therapeutics Provides Pipeline Progress and Reports..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202412:30GLOBEVerve Therapeutics to Participate in the Guggenheim..
02/1/202412:30GLOBEVerve Therapeutics to Present at the 42nd Annual J.P. Morgan..
01/12/202322:00GLOBEVerve Therapeutics Announces Closing of Public Offering of..
29/11/202322:54EDGAR2Form 8-K - Current report
29/11/202322:47EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/11/202312:47DJNVerve Therapeutics Shares Tumble Premarket After Stock Sales
29/11/202304:37GLOBEVerve Therapeutics Announces Pricing of Public Offering of..
28/11/202322:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/11/202322:01GLOBEVerve Therapeutics Announces Proposed Public Offering of..
13/11/202312:34EDGAR2Form 8-K - Current report
12/11/202321:30GLOBEVerve Therapeutics Announces Interim Data for VERVE-101..
07/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:00EDGAR2Form 8-K - Current report
07/11/202312:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
31/10/202311:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202311:01GLOBEVerve and Lilly Relationship Expands to Include Verve’s In..
23/10/202313:22DJNVerve Therapeutics Gets Clinical Hold For VERVE-101 Lifted..
23/10/202312:41EDGAR2Form 8-K - Current report
23/10/202312:30GLOBEVerve Therapeutics Announces Clearance of Investigational..
26/9/202312:30GLOBEVerve to Present Interim Data from the heart-1 Phase 1b..
21/9/202322:05GLOBEVerve Therapeutics to Participate in the 2023 Cantor Global..
18/9/202312:30GLOBEVerve Expands Leadership Team with Appointment of Frederick..
10/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:00EDGAR2Form 8-K - Current report
10/8/202312:30GLOBEVerve Therapeutics Highlights Recent Company Progress and..
03/8/202312:30GLOBEVerve Therapeutics to Present at the Canaccord 43rd Annual..
Apertura: 5,22 Min: 5,03 Max: 5,24
Chiusura: 5,23

La tua Cronologia

NASDAQ
VERV
Verve Therapeutics
CRTO
BOBAUSD
Boba Token
LSE
93YM
Telstra 2.5% 23
BIT
UC72MM
Unicredit Bank
USOTC
TIGXF
Team Internet (QX)
NASDAQ
HTIBP
Healthcare
AMEX
NFRA
FlexShares STOXX Global ...
TSXV
ALX
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network